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Abstract 
Fructans are fructose-based oligo-and polysaccharides of natural origin. Fructan 
and fructose species are sometimes confused by the great public, although they 
clearly have different biochemical and physiological properties. This review 
discusses aspects of the use of fructose and fructans in foods in the context of 
human health, with possible differential effects on cellular autophagy in cells of 
the human body. Although there are uncertainties on the daily levels of ingested 
fructose to be considered harmful to human health, there is an emerging 
consensus on the benefits of the use of fructans in functional foods, sustaining 
health via direct immunomodulatory and antioxidant effects or through indirect, 
prebiotic mechanisms.  
 
 
Abbreviations. AGEs: advanced glycation end products; ATP III: Adult 
Treatment Panel III; ChREBP: carbohydrate-responsive element binding 
protein; CVD: cardiovascular diseases; DHAP: dihydroxyacetone phosphate; 
eNOS: endothelial nitric oxide synthase; ER: endoplasmic reticulum; FA: fatty 
acid; FOS: fructo-oligosaccharides; GGT: gamma glutamyl transferase; GI: 
glycemic index; GLUT: glucose transporter; Gr43a: gustatory receptor 43a; 
HFCS: high-fructose corn syrup; IRS: insulin receptor substrate; JNK: c-jun N-
terminal kinase; NAFLD: non-alcoholic fatty liver disease; PFK-1: 
phosphofructokinase 1; PKC: protein kinase C; RBP-4: retinol binding protein-
4; ROS: reactive oxygen species; SCFAs: short chain fatty acids; SREBP-1: 
sterol regulatory element-binding protein 1; TG: triglyceride; VLDL: very-low-
density lipoproteins 
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Introduction 
Sweeteners are known since the early twentieth century when saccharin, a 
molecule 300-500 times sweeter than table sugar and developed by Constantin 
Fahlberg in 1879, became popular during the First World War 1. Since then, 
  
 
 
 
 
 
 
 
 
 
many other substances were introduced into the world market with the purpose 
to sweeten foods and beverages. Contrary to table sugar (saccharose or sucrose, 
a disaccharide consisting of glucose and fructose), they have a low or zero 
caloric (Kcal) value and minimal doses are required to obtain the same 
sweetening effect. Some of these sweeteners, currently found in any 
supermarket or added to snacks and soft drinks labelled as "light", have a 
natural origin (e.g. fructose, stevioside, xylitol), but most of them are synthetic 
(e.g. sucralose, saccharin, aspartame). Although short chain fructans, natural 
fructose-based oligosaccharides (FOS), have sweetening properties as well, 
they are less sweet than fructose and sucrose 2 and therefore they are not 
particularly used with the purpose to sweeten foods and beverages. 
Combinations of FOS and for instance stevioside 3 may lead to the desired 
reduced caloric intake and sweetening effects. Fructans are health improving 
compounds used as prebiotics and fat replacers in various foods, but they are 
interesting in terms of non-food applications as well 4. 
The difference between fructose and fructans is not always clear to the general 
public, and general misconceptions exist on their terminology and physiological 
effects. While at the end of the 70s fructose was suggested as useful addition in 
diets of diabetic patients, now it becomes clear that higher doses of fructose 
might lead to the development of pathological conditions such as metabolic 
syndrome and non-alcoholic-fatty-liver, in turn increasing risks on 
cardiovascular diseases. These effects are emphasized comparing it to fructans 
that, in contrast, have a proven beneficial prebiotic action and health improving 
effect.  
 
 
Consequences of fructose assumption in the human diet 
Fructose (C6H12O6), a hexose monosaccharide, is a ketose-type reducing sugar. 
Although its molecular formula is identical to the aldose glucose, it is clearly 
different in many chemical and metabolic facets. By linking glucose and 
fructose, sucrose is formed and the reducing character is lost.  Until the early 
nineteenth century the human diet has been characterized by the intake of a 
limited amount of sugar and sweeteners. For a long time the only source of 
fructose were fruits and honey, in which it is present at lower levels. For 
instance, the amount of fructose in a medium size raw apple is about 11 g, 
while the average fructose content in one tablespoon of honey is 9 g. The 
fructose ingested in this way and in small quantities is beneficial since it 
improves the glycaemic response after administration of glucose in subjects 
suffering from type 2 diabetes 5. It has been established by the American 
Diabetic Association that in the United States the recommended quota of 
energy derived from sweeteners should not go beyond 25% of the total energy 
but this limit is currently exceeded by a quarter of children 6. From 1970 to 
1997, the use of sweeteners has steeply increased. For example, the per capita 
fructose consumption rose from 64 g/day to 81 g/day. Fructose is mainly taken 
up in the form of sucrose and high-fructose corn syrup (HFCS), which is 
composed by either 55% or 42% of fructose 7. Based on incomplete 
assumptions, in 1986, fructose was even suggested as a low cost substitute of 
glucose for diabetic patients 8. In the same year, Levin et al. proposed that 
fructose, in contrast, does not stimulate thermogenesis, thus promoting obesity 
more than glucose 9. This initial hypothesis on the influence of fructose on the 
metabolism prompted many other studies on high fructose intake and the onset 
of metabolic syndrome and other disorders.  
According to the Adult Treatment Panel III (ATP III) Report, the metabolic 
syndrome, also known as X-syndrome, can be defined as a set of clinical 
manifestations such as abdominal obesity, atherogenic dyslipidemia, 
hypertension, insulin resistance and glucose intolerance, all predisposing factors 
to cardiovascular diseases (CVD) 10. Experiments performed on rhesus 
monkeys (Macaca mulatta), a species closely resembling the human race, 
demonstrated that a high-fructose diet caused, within a short time period of 
time, insulin resistance and many features of the metabolic syndrome as central 
  
 
 
 
 
 
 
 
 
 
obesity, dyslipidemia and inflammation. Moreover, a subset of monkeys 
developed type 2 diabetes 11. 
Spotlight on fructose metabolism and the disorders linked to its 
overconsumption 
After its intake from dietary sources, fructose is passively transported across the 
intestine membranes by GLUT5, a member of the facilitative glucose 
transporter (GLUT) family, and also an important control point for fructose 
absorption and distribution to other tissues 12 (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.  Fructose metabolism in the liver 
DHAP + GLYCERALDEHYDE 
Fructose ingested with the diet is passively translocated and absorbed within the 
enterocytes by the transporter GLUT5. Herein a part of it is conveyed by the 
portal circulation to the liver where the carrier protein GLUT2 allows the 
passage in hepatocytes. The hepatic enzyme system responsible for the 
metabolism of fructose and glucose comprises the following catalysts: 1. 
Fructokinase  2. Fructose 1,6-bisphosphate aldolase 3.  Triose-phosphate 
isomerase (Tim) 4. Fructose 1,6-bisphosphate aldolase  5. Glyceraldehyde-3-
phosphate dehydrogenase 6. Hexokinase 7. Phosphoglucose isomerase  8. 
Phosphofructokinase-1 (Pfk-1)  9. Phosphoglycerate kinase (Pgk)  10. Enolase  
11. Pyruvate kinase  12. Pyruvate dehydrogenase complex (Pdc). 
 It should be noted that in subjects with type 2 diabetes, the level of mRNA and 
proteins corresponding to the duodenal GLUT5 is up to 3-4 times higher than in 
non-diabetic subjects 13. It has been demonstrated in some patients that 
reducing the state of hyperglycaemia can normalize the up-regulation of a 
specific transporter. These observations suggest that GLUT5 might be involved 
in the metabolic perturbations linked to high-fructose nutrition 14. Once 
fructose and glucose are absorbed in enterocytes they go directly across the 
portal circulation which conveys them to the liver, where an active hepatic 
enzyme system rapidly metabolizes fructose, converting it into glyceraldehyde 
and dihydroxyacetone phosphate (DHAP), representing the connection point 
between the fructose and glucose metabolic pathways 15. 
One of the distinctive features of fructose metabolism as compared to glucose 
metabolism is that it does not rely on the activity of phosphofructokinase (PFK-
1) (Fig. 1). PFK-1 converts fructose 6-phosphate to fructose 1,6-bisphosphate 
and is pivotal in the regulation of the glycolytic flow, influencing cell 
metabolism and systemic metabolic conditions. Given its central role, this 
enzyme is controlled by the concentration of an high number of metabolites 
such as AMP, ADP and fructose 2,6-bisphosphate which act as activators and 
ATP, phosphoenolpyruvate (PEP) and citrate that inhibit PFK-1 16. 
In contrast to glucose, the peptide hormone insulin is unable to influence the 
hepatic metabolism of fructose and its conversion to triose phosphates. Thus 
  
 
 
 
 
 
 
 
 
 
fructose enters the glycolytic pathway unhindered and generates an excess of 
energy flux caused by the low Km of the enzyme fructokinase and the 
concomitant lack of a negative feedback from ATP or citrate. Direct 
consequence is a transient depletion of free phosphate and a decrease in the 
ATP concentration in the hepatocytes. Triose phosphates produced from 
fructose can subsequently be converted into pyruvate and oxidized to CO2 and 
H2O in the tricarboxylic acid cycle. Alternatively, they might be converted in 
fatty acids triggering the process of de novo lipogenesis 17 (Fig. 1). 
Another hypothesis, explaining the propensity of fructose to lead to lipogenesis, 
states that the very rapid phosphorylation of fructose by fructokinase stimulates 
triglyceride synthesis via a purine-degrading pathway. Indeed, the generated 
AMP enters the purine degradation pathway through the activation of AMP 
deaminase, uric acid production and the generation of mitochondrial oxidants. 
These oxidants negatively interact with aconitase, which catalyses the 
conversion of citrate to isocitrate in the Krebs cycle, causing the accumulation 
of citrate and the stimulation of ATP citrate lyase and fatty-acid synthase, 
finally leading to the induction of de novo lipogenesis 18. This might explain 
why hepatic ATP depletion (and impaired ATP recovery), and elevated uric 
acid levels are considered as risk factors for the development of non-alcoholic 
fatty liver disease (NAFLD) 19. 
Cox et al. (2012) reported that an intake of fructose (corresponding to 25% of 
energy requirements) for 10 weeks contributes to characteristic features of 
metabolic syndrome by increasing the amounts of circulating uric acid, the 
activity of gamma glutamyl transferase (GGT) linked to changes in liver 
functionality and the production of retinol binding protein-4 (RBP-4) 20. High 
values of RBP-4 were also observed in women with NAFLD 21. 
An additional hypothesis was launched relating fructose intake with 
hyperuricemia and the onset of insulin resistance. This hypothesis is based on 
the fact that insulin, through the activation of the endothelial enzyme nitric 
oxide synthase (eNOS), can increase the blood flow to the skeletal muscles, in 
this way influencing glucose utilization 22. The eNOS is strongly inhibited by 
high concentrations of uric acid, which might block the vascular effects of 
insulin and thus induce a state of insulin-resistance linked to the fructose 
assumption 23. 
At the end of the 70s, one of the reasons behind the erroneous suggestion of 
administrating fructose to diabetic patients, as a valid alternative to glucose, is 
its low glycemic index (GI). In fact the glycemic index of fructose is 20, a very 
low value as compared to glucose with a GI of 100. The GI is considered to 
reflect the capability of a particular carbohydrate to raise the rate of glycaemia, 
thus, it can be a useful parameter to describe and compare diverse nutrients 
according to the different induction of plasma glucose production after their 
ingestion 24. Furthermore, the GI influences the degree of satiety that an 
aliment is able to confer because there is a correlation between insulin 
production and leptin stimulation. According to Klok et al. (2007), leptin is a 
mediator of the long-term regulation of energy balance, suppressing food intake 
and thereby inducing weight loss 25. Since fructose does not stimulate insulin 
secretion by pancreas β cells, it reduces a leptin level that in turn is not able 
anymore to reduce the appetite 26. Based on this view, Shapiro et al. (2008) 
hypothesized that chronic fructose consumption leads to leptin resistance, 
which subsequently may promote the development of obesity in response to a 
high-fat diet 27. In obese subjects with insulin resistance, consumption of 
fructose compared with glucose, in the form of soft drinks during meals, has 
been related with a decreased production of insulin, a leptin weak diurnal 
activity and an enhanced concentration of triglycerides (TGs). These increases 
indicate that fructose consumption may aggravate the impaired metabolic 
profile typical in overweight individuals. Other experiments on rats, instead, 
show that an acute fructose uptake creates a state of leptin resistance though an 
enhanced amount of cytokine 3 suppressor and through a decreased 
serine/threonine phosphorylation of key proteins in leptin signaling. In the liver 
leptin elicits fat mobilization and oxidation, thus, a fructose-induced leptin 
resistance might lead to the development of NAFLD 28. 
It has already been mentioned that one of the postulated consequences linked to 
abuse of fructose is the development of type 2 diabetes, which is a condition 
  
 
 
 
 
 
 
 
 
 
often proceeded by a state of insulin resistance 29. Indeed, a high fructose diet 
increases glucose and insulin responses to sucrose load, increasing fasting 
glycaemia, and leading to hepatic insulin resistance in healthy men 30. The 
early stages of type 2 diabetes are characterized by a condition of 
hyperinsulinemia, with a concomitant increase in the levels of C-peptide (a 
polypeptide derived from pro-insulin in the pancreas). The C-peptide blood test 
allows distinguishing between diabetes type 1 and 2 in the disease early-stage. 
A patient with a pancreatic dysfunction and incapable of producing insulin 
(type 1 diabetes) is also unable to produce the C-peptide since it is a by-product 
of insulin maturation. On the other hand in the occurrence of type 2 diabetes, as 
in this case, the level of C-peptide are usually normal or even higher due to a 
reduced sensitivity of cells to insulin action which in turn might cause a state of 
insulin resistance. Only at the stage of overt metabolic disorder, the chronic 
overload of the pancreas trying to compensate for the deficiency at the cellular 
level, leads to a progressive decay of pancreatic β-cell function and thus 
insufficient insulin secretion. In a population study on 1999 healthy women, 
plasma C-peptide concentrations were recorded. Overall, high intakes of 
fructose and high glycemic foods were associated with a higher C-peptide 
concentration, suggesting that high fructose intake might play a role in the 
development of insulin resistance and type 2 diabetes 31. There is a tight 
association between lipid metabolism disorders and insulin resistance; indeed 
an excessive intramyocellular triacylglycerol combined with a reduced lipid 
turnover may produce toxic lipid-derived metabolites, such as diacylglycerol, 
fatty acyl CoA, and ceramides which, in the intracellular environment, lead to a 
higher serine/threonine phosphorylation of the insulin receptor substrate-1 
(IRS-1), reducing insulin signaling. An alteration in the post-receptor insulin 
signaling was proposed in rodents 32. 
The administration of high-sucrose diet for three weeks did not alter the number 
of insulin receptors (IRS-1 and IRS-2), but their activity was affected by an 
elevated basal phosphoinositid-3-kinase leading to a reduction of their degree of 
phosphorylation 33. In a similar experiment, rats were fed for 28 days with a 
high-fructose diet, and also in this case, as for the high-sucrose diet, a reduction 
in the IRS 1 and 2 phosphorylation were recorded, both in the liver and in 
muscles 34. Samuel et al. (2010) suggested that toxic compounds such as 
diacylglycerol activate a novel protein kinase C (novel-PKC). The activation of 
PKCs is notably involved in the regulation of insulin activity through their 
effect on serine phosphorylation of IRS1 35. However, which kinase(s) are 
involved in the serine phosphorylation of IRS remain(s) unknown. What is 
known is that the phosphorylation of IRS1 at serine-307 prevents IRS1 from 
interacting with the insulin receptor. This leads to a consequent decrease in the 
tyrosine-phosphorylation of the insulin receptor, resulting in increased hepatic 
glucose production, impaired glucose tolerance and increased fasting glucose 
and insulin concentrations that may contribute to the development of 
hyperglycaemia and type 2 diabetes 36 (Fig. 2).  
 
Fig. 2. Effect on high-fructose diet on the activity of insulin receptor substrate 1 
and 2 
The status of insulin resistance induced by high-fructose administration is 
correlated with modifications in the early steps of insulin signal transduction. 
In the regular process insulin triggers the tyrosine kinase activity of its receptor 
resulting in the tyrosine phosphorylation of pp185, which contains insulin 
receptor substrates IRS-1 and IRS-2. Feeding animals a high-fructose diet 
results in insulin resistance, which is not related to the IRS-1 /2 protein levels 
but it is due to a decreased phosphorylation of the insulin-induced pp185 (IRS-
  
 
 
 
 
 
 
 
 
 
1/2). Moreover the intracellular accumulation of lipids, which is correlated with 
a high-fructose diet, activates the novel protein kinases C (novel PKC) with 
subsequent impairments in insulin signaling caused by the phosphorylation of 
the serine-307 in IRS1 which prevents its interaction with the insulin receptor. 
 
It has also been found that high doses of fructose administered by intraportal 
infusions (portal vein fructose concentration >1 mmol/L), trigger a hepatic 
stress response identified by the activation of c-jun N-terminal kinase (JNK). 
When the level of hepatic fructose uptake goes beyond the need of glycogen 
and energy production, mechanisms of adaptive response to stress are 
established. In these conditions an increased phosphorylation of the mitogen-
activated protein kinase kinase-7 (MKK7) has been observed, which is capable 
of activating JNK that, in turn, associates with c-jun N-terminal kinase-
interacting protein-1(JIP1). In the liver the activation of JNK leads to the 
phosphorylation of serine-307 on IRS-1 37. 
As explained above, high intake of fructose can strongly stimulate lipogenesis. 
An overload of the lipid-export machinery and the disturbed mitochondrial lipid 
degradation lead to intrahepatic fat deposition or steatosis 38. In healthy 
volunteers, the intake of fructose in high quantities increased plasma total 
lipoproteins and very-low-density lipoproteins (VLDL). Moreover, fructose 
may contribute to the biogenesis of both glycerol and the fatty-acyl parts of 
VLDL-triglycerides 39. In rats, the in vivo administration of [14C]fructose led 
to 14C incorporation in liver lipids 40. A similar experiment demonstrated the 
stimulation of hepatic de novo lipogenesis after acute fructose uptake in 
humans, detecting the inclusion of infused 13C-labeled acetate into VLDL-
palmitate 41. Further, fructose causes the concomitant inhibition of fatty acid 
oxidation in the mitochondria of hepatocytes. Fructose-mediated malonyl-CoA 
increases inhibit the carnitine palmitoyl transferase-1 (CPT- 1), reducing the 
translocation of fatty acids into the mitochondria 42. Fructose has also the 
ability to stimulate the induction of hepatic lipogenic enzymes, such as the 
transcription factor sterol regulatory element-binding protein 1 (SREBP-1c), in 
a process that is totally independent from the action of insulin, the main inducer 
of hepatic lipogenesis 43.  
All these above-mentioned processes are considered as evidence in favor of the 
hypothesis that dietary fructose might promote the development of NAFLD, 
which can culminate in hepatic insulin resistance, often the first sign of an 
increased risk on developing type 2 diabetes 44. 
 
 
 
Fructose effects are under debate 
Despite the large amount of data on fructose feeding experiments, the issue 
remains controversial.  Perhaps the doses used in some of the above-mentioned 
experiments were far too high 45. The long-term effects of moderate, daily 
fructose intakes (e.g. by drinking a soda per day) remain ambiguous. Some 
recent researches suggest that fructose consumed in a typical diet, as part of 
commonly used sweeteners such as sucrose or HFCS, is not able to promote the 
deposition of ectopic fat in the liver or muscles. Recently White (2013) 
predicted that fructose intake, in accordance with normal population habits, is 
not able to alter biochemical outcomes more than any other dietary sugars; and 
moreover Laughlin (2014) claim that modest level of fructose might acts 
synergistically with glucose increasing the disposal of a dietary carbohydrate 
load 46. Nevertheless, a meta-analysis was conducted with a dosage that 
resembled the average daily intake in the United States (>50 g/day). Such levels 
are associated with increased postprandial TG range. A fructose intake >100 
g/day has been associated with increased fasting TGs 47. In a recent study a 
double-blind, randomized, cross-over trial has been performed in healthy young 
men by feeding them for three weeks with 600 mL a day of four different 
sweetened beverages containing medium fructose (MF) at 40 g/day, high 
fructose (HF), high glucose (HG), and high sucrose (HS) each at 80 g/day. The 
results showed that fructose, as compared with glucose, is able to alter in a 
significant way the hepatic insulin sensitivity and lipid metabolism 48. It can 
be concluded that these last two examples instantiate the need for further 
  
 
 
 
 
 
 
 
 
 
studies on this topic, rather than using them as a support against the use of 
fructose in food applications. 
 
 
 
Fructans: beneficial for health 
Fructans are fructose-based oligo- and polysaccharides containing maximal one 
glucose unit. They have different and unique properties as compared to their 
fructose constituents and as compared to glucans (polymers of glucose) 49. 
Five main fructan subgroups can be defined on the basis of the position of 
glucose moieties (internal or end position) and on the glycosidic linkages 
between their fructosyl residues [50] (Fig. 3). A sixth subgroup was proposed, 
consisting of mixed neo-type graminans, also termed agavins [51]. The best 
studied linear inulin-type fructans, typically occurring in Asteracean species, 
contain fructose units linked through β-2,1 bonds. 1-kestotriose (1-kestose) is 
the building block of this series. In plants, it is produced by the activity of 
sucrose:sucrose 1-fructosyl transferase (1-SST), transferring a fructosyl residue 
from a donor to an acceptor sucrose substrate. Fructan:fructan 1-fructosyl 
transferase (1-FFT) then polymerizes 1-kestotriose into higher DP inulin-type 
fructans. Sucrose:fructan 6-fructosyl transferase (6-SFT) preferentially transfers 
a fructosyl moiety from sucrose to 1-kestotriose, producing 1&6-kestotetraose 
(also termed bifurcose), the smallest graminan-type of fructan with mixed type 
of linkages, as typically occurring in cereals. Next, bifurcose can be further 
extended by 6-SFT and 1-FFT, leading to higher degree of polymerization (DP) 
graminans. Linear levan-type fructans, as occurring in some fodder grasses, 
have only β-2,6 fructosyl-fructose bonds and are synthesized by a 6-SFT with 
intrinsic sucrose:sucrose 6-fructosyl transferase characteristics (a 6-SST/6-SFT) 
[52]. The enzyme fructan:fructan 6G-fructosyl transferase (6G-FFT) 
synthesizes 6G-kestotriose (6G-kestose, neokestose) from 1-kestotriose as 
donor substrate and sucrose as acceptor substrate. Elongation by 1-FFT and 6-
SFT leads to the formation of inulin neoseries and levan neoseries as for 
instance occurring in asparagus and Lolium species, respectively [50] (Fig. 3).  
 
 
Fig. 3. Plant fructan biosynthesis from sucrose 
Five classes can be discerned: inulin- (linear), levan- (linear), graminan-
(branched), neo-inulin (branched) and neo-levan type (branched) fructans. The 
following enzymes are involved: sucrose:sucrose 1-fructosyl transferase (1-
SST),    a dual function sucrose:sucrose 6-fructosyl  transferase/ 
sucrose:fructan  6-fructosyl  transferase (6-SST/6-SFT), sucrose:fructan  6-
fructosyl  transferase  (6-SFT),    fructan:fructan  6G-
fructosyl  transferase  (6G-FFT)  and  fructan:fructan  1-
fructosyl  transferase  (1-FFT). The trisaccharides 1-kestose, 6-kestose and 
neokestose and the trisaccharide bifurcose are building blocks from which 
higher degree of polymerization (DP) fructans are synthesized.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
We refer to Incoll and Bonnett (1993) for more info on the occurrence of the 
different fructan types in (food) plants [53]. While plants need at least two 
distinct enzymes to catalyse priming and elongation, microbial fructan 
biosynthesis typically occurs by a single fructosyltransferase activity for both 
reactions, creating either levan- type fructans by levansucrases or inulin-type 
fructans by inulosucrases [54].  
The best known plant-derived fructans in the food industry are inulin, 
oligofructose and fructo-oligosaccharides (FOS) because of their well-
recognized prebiotic and health-improving effects 55. Inulin is usually derived 
from chicory roots, and their partial hydrolysis yields oligofructose, which is 
also commonly referred to as “FOS”, but it has a plant origin. Fungal β-
fructosidase activity on sucrose leads to the synthesis of FOS 56. Fructans in 
human diets originate from wheat (Triticum aestivum), rye (Secale cereale), oat 
(Avena sativa), barley (Hordeum vulgare), leek (Allium ampeloprasum), 
Belgian endives (Cichorium intybus), lettuce (Lactuca sativa), salsify 
(Scorzonera hispanica), onion (Allium cepa), garlic (Allium sativum), globe 
artichoke (Cynara scolymus) and asparagus (Asparagus officinalis)57. The 
latter four species are extensively used in medicine with reported 
immunomodulatory and antiviral properties 57. Wheat is by far the most 
important fructan source in the Western diet, as it accounts for approximately 
70% of the daily fructan intake in the American and Western Europe diets 58. 
Therefore, research is now focusing more on the metabolism and food 
applications of cereal fructans. Branched Agave-derived fructans may have 
similar properties and applications as cereal fructans 59. 
Contrary to fructose, fructans (i) are not digested by the human upper gastro-
intestinal tract 50, (ii) induce satiety-sensing in food consumption and (iii) 
counteract lipogenesis in the liver 30. How can inulin-type fructans in our diet 
contribute to sustain health and overall well-being? They may act by selective 
stimulation of benefical bacteria (e.g. Lactobacilli and Bifidobacteria) 60, 
relieve of constipation 61, lowering of blood glucose levels 62, improved 
mineral uptake 63, reduction in blood serum triacylglycerol levels 64, 
reduction of colon pH 56, increased production of SCFAs 56, reduced risk 
of colon cancer 65, stimulation of the immune system 66 and growth 
inhibition of pathogenic microorganisms 67. We refer to our previous lengthy 
reviews for more elaborated descriptions and discussions on possible 
underlying mechanisms 55, 62. Although dietary fructans generally mediate 
positive effects, it should be noted that doses exceeding 20 g/day may lead to 
abdominal pains and flatulence 68.  
Historically, the positive effects of fructans on human health have been 
explained through indirect mechanisms via their positive influence on intestinal 
microflora 57 (Fig. 4). However, this view is now rapidly changing in favour 
of more direct mechanisms (Fig. 4).  
 
 
 
 
 
 
 
 
 
 
Fig. 4.  
Simplified model depicting direct and indirect effects of fructans at the gut 
interphase 
Dietary fructans stimulate the growth of beneficial bacteria (Bifidobacteria, 
Lactobacilli) that ferment fructans to SCFA and gases (e.g. H
2
) in the gut. After 
their uptake in gut epithelium cells, SCFA trigger AMPK/NFkB and other 
  
 
 
 
 
 
 
 
 
 
signaling pathways leading to local or systemic (e.g. the liver) 
immunomodulatory effects. Dietary fructans (and other carbohydrates) may 
also directly stimulate TLR2/TLR4 signaling, linked to similar downstream 
signaling pathways and immunomodulatory effects promoting health. 
Additionally, beneficial bacteria produce a number of compounds that, after 
uptake in to the gut epithelium, promote overall health and well-being. AMPK: 
AMP-activated kinase; NF-κB: nuclear factor kappa-light-chain-enhancer of 
activated B cells; SCFA: short chain fatty acids; TLR: Toll-Like Receptor.  
 
In plants, fructans and other organic compounds occurring at elevated 
concentrations are more and more recognized as “antioxidants” that can be 
involved in the scavenging of hydroxyl radicals, contributing to cellular ROS 
homeostasis [69]. Moreover, similar processes might occur in foods and at the 
gut interphase in animals and humans [70]. Therefore, fructans may be useful in 
disease prevention by reducing ROS levels. It is well-known that an array of gut 
diseases are associated with ROS dynamics [70]. The antioxidant capacity of 
inulin was recently confirmed in ex vivo experiments [71].   
Defense in plants relies on innate immunity responses, in contrast to higher 
vertebrates that rely both on innate and adaptive immunity [59]. The importance 
of the role of autophagy in innate and adaptive immunity is highlighted by the 
association of defects in autophagy with neurodegeneration, aging, cancer, 
metabolic syndrome and inflammatory disorders such as Crohn's disease [72]. It 
was recently proposed that fructans and other sugars may act as 
immunomodulatory signals in all eukaryotes [73]. The basis of this idea comes 
from the finding that inulin-type fructans trigger Toll-Like-Receptor (TLR2, 
TLR4) signaling pathways, intimately linked to Nuclear Factor kappa-light-
chain-enhancer of activated B cells (NF-kB) and AMP-activated kinase 
(AMPK) signaling pathways [57] (Fig. 4). AMPK is an energy-sensing protein 
kinase complex that monitors the metabolic status to maintain energy 
homeostasis [74]. Nutrient starvation leads to increased AMPK activity that 
stimulates autophagy, while mammalian target of rapamycin complex 1 
(mTORC1) has the opposite effect [75].  Intriguingly, both inulin-type fructans 
and its fermentation products (e.g. butyrate) stimulate AMPK signaling [76] 
that stimulates autophagy. Whether inulin binds to membrane receptors or 
rather stimulates endocytotic (and autophagic) mechanisms, perhaps mediating 
its own uptake [77], remains a matter of debate. 
Intriguingly, besides fructans, exogenously applied disaccharides sucrose and 
trehalose are emerging as sweet immunity agents in plants, stimulating stress 
responses. Similar to extracellular ATP, these sugars may be perceived as 
Damage Associated Molecular Patterns (DAMPs) [70]. Sucrose was reported to 
stimulate endocytosis and autophagy [78] Trehalose also stimulates autophagy 
[79]. In the context of neurodegenerative diseases, autophagy is proposed to 
remove the initial damaged mitochondria and aggregated proteins, leading to an 
effective antioxidative strategy, counteracting further neurodegeneration [80]. 
Thus, autophagy seems to emerge as an essential cell biological process in 
eukaryotic cells, and a central component of integrated stress responses, 
preventing and counteracting numerous diseases [73]. While fructans, sucrose 
and trehalose stimulate autophagy, fructose shows the opposite effect. 
Regardless of the need to further unravel the complexity of all the above-
mentioned pathways, there is a general consensus within the scientific 
community that fructans are to be considered as functional foods and health-
promoting compounds, as explained in more detail in our previous reviews [50, 
57].  
 
Conclusion   
Both fructose and fructans are natural products available and assimilated 
through fruits and vegetables, and both are currently used as sweeteners. 
Although fructose and fructans are related and often confused by non-experts, 
they are absorbed and metabolized in a different way, and their physiological 
effects in the human body are entirely different, for instance with respect to 
their prebiotic capacities and their differential effects on AMPK signaling and 
autophagy, associated with possible disease prevention. According to the data 
collected so far we conclude that fructans benefit health as prebiotics, 
  
 
 
 
 
 
 
 
 
 
antioxidants and immunomodulators, while fructose abuse (e.g. as sweeteners 
derived HFCS) may lead to opposite effects, although there remain huge 
uncertainties on the daily amounts of ingested fructose that could be considered 
harmful to human health, and this requires further investigations.  
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